From Investing.com: 2024-06-19 21:45:10

Vanda Pharmaceuticals rejected takeover offers from Future Pak and Cycle Pharma, citing undervaluation. Future Pak’s revised bid raised the cash portion to $8.50-$9.00 per share, with contingent value rights of $4.27 per share. Cycle Pharma’s offer of $8/share would value Vanda at $466 million. Vanda’s board deemed both offers inadequate.



Read more at Investing.com: Vanda rejects Future Pak and Cycle Pharma’s takeover offers By Reuters